Friday, December 30, 2016 4:33:02 AM
HTTP://immunosym.org/program/poster-sessions
Poster Session A: Humoral Immunity for Diagnosis and Therapy, Immune Checkpoints and Stimulatory Receptors, and Therapies Targeting T cells
Thursday, February 23 2017: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM
BOARD H3
MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial. (Abstract 154)
First Author: Martin Scurr
HTTP://medicine.caerdydd.ac.uk/media/filer_public/85/a0/85a0407a-e02a-4086-bfb3-6fc902eb7ecc/science_in_practice_infection__immunity_2014.pdf
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM